Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
Cedars-Sinai Medical Center, Los Angeles, California Mayo Clinic - Florida (Inflammatory Bowel Disease Center), Jacksonville, Florida Corewell Health, Grand Rapids, Michigan Mayo Clinic Department of Gastroenterology, Rochester, Minnesota Washington University School of Medicine, St Louis, Missouri NYU Langone Health, New York, New York University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Penn State Health (Milton S. Hershey Medical Center), Hershey, Pennsylvania Last updated February 2025